Clinical Trial Update: A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms [Phase 1]

View source ↗

Summary

Phase 1 safety, tolerability and preliminary efficacy study of NC525 in adults with advanced myeloid neoplasms has been terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• NC525

Snippet

Sponsor: NextCure, Inc. | Conditions: Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2026-01-28